Overview
Treatment Considerations for PAH Patients During the Pandemic
Expert Insights
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are you taking the right precautions to ensure your patients with PAH are safely managed during COVID-19? Are you employing effective therapeutic management strategies with your PAH patients during the pandemic? In this short CME-certified vlog, leading pulmonologist Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center, discusses how to effectively manage therapy for PAH during the pandemic, including those who are COVID-19-infected, taking into account the evidence and guidelines to facilitate effective therapeutic management.
This activity is intended for pulmonologists, cardiopulmonologists, cardiologists, and AHPs managing patients with PAH.
Clinicians who manage patients with PAH require increased competency in managing therapeutic regimens, including in those who are infected with COVID-19. It is critical for PAH patients to take precautions against COVID-19 to prevent disease progression and for physicians to ensure patients are well controlled to decrease the risk of severe illness if a patient does become infected. Upon completion of this activity, clinicians will be better able to facilitate effective therapeutic management and perform timely treatment adjustments to ensure better patient outcomes during the COVID-19 pandemic.
Upon completion of this activity, participants will be able to:
• Recommend treatment selection and management for different PAH functional classes and risk classifications during the pandemic
• Review the latest epidemiological data to develop risk mitigation strategies in PAH patients
• Recommend treatment selection and management for different PAH functional classes and risk classifications during the pandemic
• Review the latest epidemiological data to develop risk mitigation strategies in PAH patients
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Victor Tapson, MD
Professor of Medicine
Director, Venous Thromboembolism and Pulmonary Vascular Disease Research Program
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Embolism Response Team
Cedars-Sinai Medical Center
Los Angeles, CA
Professor of Medicine
Director, Venous Thromboembolism and Pulmonary Vascular Disease Research Program
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Embolism Response Team
Cedars-Sinai Medical Center
Los Angeles, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Victor Tapson, MD, (Faculty)
Advisor or Review Panel Member: Bristol Myers Squibb, Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Occasional): Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Retained): Thrombolex, Inc. and V-Wave Ltd.
Grant/Research Support Recipient: Bristol Myers Squibb, Eli Lilly and Company, Genentech, United Therapeutics, Verily Life Sciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: EUA vaccines and therapies for COVID-19
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
